5/31/20

Impact Biomedical and GRDG Sciences Announce Medical Technology Package Valued at USD 1.39 Billion (SGD 1.97 Billion) by Independent Experts

SINGAPORE, Jun 1, 2020 - (ACN Newswire) - SGX-listed Singapore eDevelopment Limited's (the "Company") (SeD; SGX:40V) wholly owned subsidiary, Impact Biomedical Inc. ("Impact Biomedical"), would like to update its stakeholders on its suite of antiviral and medical technologies ("Suite"). This Suite is valued at USD 1.39 Billion (SGD 1.97 Billion) as of 26 May 2020 by another independent valuation experts which are reputed for their expertise and skills in assessing the potential deal value of medical intellectual property. The Suite is mainly co-owned by Impact Biomedical and its scientific research partner, Global Research and Discovery Group Sciences ("GRDG Sciences"). Impact Biomedical's ownership in the Suite equates to a value of approximately USD 933 Million (SGD 1.32 Billion).

Impact Biomedical previously announced on 23 April 2020 that the Suite was valued at USD 592 million (SGD 841 million) by Destum Partners. Unlike the previous valuation, the new valuation of the Suite conducted, which was initiated by GRDG Sciences, takes into consideration numerous additional disease applications of the Suite. The scope of the new valuation of the Suite includes: 3F Mosquito and Antiviral Biofragrance; Equivir, an OTC medication with broad antiviral activity; Laetose, an advanced sugar replacement that is reduced calorie and low glycemic; and Linebacker, a broad-spectrum universal therapeutic.

The Company refers to its announcement on 4 May 2020 in relation to Impact Biomedical's entry into a share exchange agreement for a proposed US$50 million share swap. The Company wishes to state that as the terms of the share swap transaction has been finalized prior to the new valuation, the new valuation amount of the suite will not vary the terms and consideration of the share swap transaction.

Impact Biomedical and GRDG Sciences developed this Suite in a long-term research program adhering to the principles and initiatives established by the Panacea program, the Open Air Defense Initiative, Project Bioshield and the Biomedical Advanced Research and Development Authority ("BARDA") of the U.S. Department of Health and Human Services.

3F Biofragrance was designed for the Open Air Defense Initiative, a strategy to protect locations where large numbers of people gather or transit such as airports, containment areas, train stations, convention centers, hospitals, and other appropriate enclosed spaces, and ports of entry. 3F Mosquito Biofragrance and Mosquito Booster are a multi-aspect inhibitors of mosquito receptors that shut down the ability of the insects to detect human prey and they deactivate the feeding impulse. 3F Antiviral Biofragrance has proven to be successful against E. coli, MRSA, Influenza, Rhinovirus, Tuberculosis, and COVID-19. All three Biofragrance technologies are patent pending and were valued for their mosquito repellent, mosquito repellent boosting, and antimicrobial disinfectant applications.

Equivir was created as a solution for Project Bioshield, a U.S. government program to conduct and support research and development activities for countermeasures in biological emergencies. Equivir is a patented OTC medication/vitamin that has broad antiviral efficacy and was valued for its use as a prophylactic and treatment against multiple types of Influenza, Rhinovirus, Cholera, Ebola, and COVID-19.

Linebacker was modeled to shadow the Panacea program created by the US Defense Advanced Research Projects Agency ("DARPA"). Panacea was a research program designed to provide novel, multi-target therapeutics for unmet physiological needs. Linebacker is a patented universal therapeutic medication and was valued for its demonstrated effectiveness against neurological diseases including Parkinson's, 17 types of cancer, and multiple pathogens such as MRSA, E. coli, A. baumannii, K. penumoniae, S. flexneri, Cholera, Influenza, SARS, MERS, Malaria, and COVID-19.

Laetose is a reduced calorie and low glycemic sugar replacement created to address the rising global problem of metabolic disorders and associated conditions such as obesity and diabetes.

GRDG Sciences's Chief Scientific Advisor is Dr. Roscoe M. Moore, Jr., the former United States Assistant Surgeon General and former Epidemic Intelligence Service Officer at Centers for Disease Control and Prevention or CDC. He said, "GRDG's broad set of technology clearly shows a comprehensive approach to provide solutions to global healthcare that is poised to make a real impact and improve the lives of many people around the world."

Also advising GRDG Sciences is Lieutenant Colonel William H. Lyerly Jr., retired Career Senior Executive / Scientific Professional from the U.S. Department of Homeland Security and retired U.S. Army Medical Service Corps Officer. Lieutenant Colonel Lyerly also served as a senior official in the U.S. Department of Health and Human Services, the U.S. Agency for International Development, and the U.S. Executive Office of the President (White House). Lieutenant Colonel Lyerly states, "GRDG has a wide range of novel, unique capabilities which are reflected in this valuation. Each aspect is important on its own and the combination of assets is simply astounding."

Impact Biomedical accomplished this research and development in strategic partnership with GRDG Sciences led by Mr. Chan Heng Fai, Chairman. "I am greatly encouraged with the results and the team's contribution to this cause. We hope this will eventually prove to be beneficial to everyone and we look forward to more exciting discoveries" said Mr. Chan.

Daryl Thompson, Director of Scientific Initiatives and founder of GRDG Sciences said, "This valuation validates the 5-year project to prove the speed in which biomedical countermeasure research can be achieved, a major accomplishment especially in the present atmosphere of the COVID pandemic." GRDG Sciences is working with large global companies and organizations to license and integrate this technology into pipelines and programs for further validation, regulatory approval, and deployment to treat or prevent multiple threats to the health of people worldwide.

Shareholders and potential investors of SeD are advised to read this Press Release and any further announcements made by SeD carefully. Shareholders and potential investors of SeD are advised to refrain from taking any action with respect to their securities in SeD which may be prejudicial to their interests, and to exercise caution when dealing in the securities of SeD. Shareholders and potential investors of SeD should consult their stockbrokers, bank managers, solicitors or other professional advisers if they have any doubt about the actions they should take.

About Singapore eDevelopment Limited
Incorporated on 9 September 2009 and listed on the Singapore Exchange in July 2010, Singapore eDevelopment Limited is involved in (i) property development and investments primarily in the United States and Western Australia; (ii) information technology-related businesses; (iii) development, research, testing, manufacturing, licensing and distribution of biomedical products; and (iv) investment activities. For more information, please visit: www.SeD.com.sg or email contact@sed.com.sg.

About Impact BioMedical, Inc.
Impact BioMedical, Inc. ("Impact BioMedical") is a wholly-owned direct subsidiary of Global BioMedical Pte. Ltd., which in turn is a wholly-owned direct subsidiary of Singapore eDevelopment Limited, a company listed on the Singapore Exchange. Impact BioMedical strives to leverage its scientific know-how and intellectual property rights to provide solutions that have been plaguing the biomedical field for decades. By tapping into the scientific expertise of GRDG Sciences, LLC. and Australian Exchange-listed Holista CollTech Limited, Impact BioMedical pledges to undertake a concerted effort in the R&D, drug discovery and development for the prevention, inhibition, and treatment of neurological, oncological and immuno related diseases.

About GRDG Sciences, LLC.
GRDG Sciences, LLC is an advanced research team formed in Florida by natural products discovery drug research scientist, Daryl Thompson. For more information, please visit: http://www.globalrdg.com.

Copyright 2020 ACN Newswire. All rights reserved. www.acnnewswire.com

source http://www.acnnewswire.com/press-release/english/59305/

TOYOTA、カローラ スポーツに精悍さを際立たせた特別仕様車を設定

Toyota City, Japan, Jun 1, 2020 - (JCN Newswire) - TOYOTAは、カローラ スポーツを一部改良するとともに、精悍さを際立たせた特別仕様車 G"Style Package"、HYBRID G"Style Package"を設定し、全国のトヨタ車両販売店を通じて、6月1日に発売しました。

特別仕様車 G"Style Package"、HYBRID G"Style Package"は、「G」および「HYBRID G」をベースに、ブラック塗装の16インチ専用アルミホイール、Bi-Beam LEDヘッドランプ、LEDデイライト、LEDフロントフォグランプなどを特別装備。さらに、フロントロアグリルのフレーム部にサテンクロムメッキ、リヤバンパーにクロムメッキ加飾を施し、より精悍なスタイルを実現しました。

内装では、ファブリックの快適性と革の質感をあわせ持つレザテック(R)*1と合成皮革を組み合わせたブラックの専用シート表皮を採用したスポーティシート、高精細の7.0インチTFT*2カラーマルチインフォメーションディスプレイを特別装備した魅力的な仕様としました。

同時に、カローラ スポーツ全車の一部改良を実施し、外板色に新色のグレーメタリックとプラチナホワイトパールマイカ*3を設定。あわせて、新色とアティチュードブラックマイカを組み合わせたツートーン*4を設定しました。さらに、一部グレード*5に快適性を高めるシートヒーターを標準装備しました。

本リリースの詳細は下記URLをご参照ください。
https://global.toyota/jp/newsroom/toyota/32256554.html

概要:トヨタ自動車株式会社

詳細は http://toyota.jp/ をご覧ください。



Copyright 2020 JCN Newswire. All rights reserved. www.jcnnewswire.com Via JCN Newswire https://ift.tt/2pbRN02

Fight to Fameはグローバルイベントを統合する?ハーバード大学がBMSを推薦

BANGKOK, Jun 1, 2020 - (JCN Newswire) - 数日前、Fight To Fame BMSのユニークなビジネスモデルがハーバード大学のブロックチェーン研究所に注目された。ハーバード大学は公式ウェブサイトの特別記事で「BMSがエンターテイメントとスポーツの新時代をリードする能力と機会を持っていると見なされた。今まで、これが一番成功的な考えが証明される」と掲載した。

Fight To Fame BMSイベントとアクションスターリアリティショーは暗号通貨フィールドにおける独自なブロックチェーン+映画+スポーツ利益モデル(つまりBMS)、世界中のボクシングファンと映画ファンによって発行されたFFトークンがウェルススペースとバリュースペースでビットコインと競合できる唯一の暗号通貨と見なされた。その記事では、コロナーが発生した後、ハーバードブロックチェーン研究所が投資、産業、消費を軽資産からデジタル資産に変換およびアップグレードすることを重視したことと示している。

ハーバード大学の公式ウェブサイトのブロックチェーンラボにある「ゲームやテレビ/ストリーミングメディアなどの暗号通貨とエンターテインメント産業が実際にどのように連携するか」という最新の特集記事によると、「暗号通貨はゲームやテレビ/ストリーミングメディアなどの業界に対し、潜在的な影響の範囲が大きい」。また「エンターテイメントは常に驚くべきグローバルな影響力を持っている」述べた。研究所はこの視点から詳しく説明した。「過去数か月間、私たちはFight To Fame BMSからブロックチェーンの卓越したパフォーマンスを了解した。それはFFトークンがアスリート登録、イベント、アクションスターリアリティショー、新世代のチャンピオンから、新世代のハリウッドアクションスーパースターを作成すること」と述べた。

Fight To Fame BMSグローバルオペレーション委員会の委員長であり、2回のエミー賞を受賞したTimによると、Fight To Fameはブロックチェーンテクノロジーを通じ、グローバルスポーツプレーヤー、eスポーツ、スポーツイベント、アクションスターリアリティショーから登録し、新世代のチャンピオンを授与し、アクションスターを育成し、ハリウッドに入った。そして、Fight To Fameの投資したハリウッドの名作でボクシングチャンピオンをスタローン、シュワルツェネッガー、ボルダージョンソン、ジェットリー、ジャッキーチャンなどの国際的なアクションスーパースターになれさせる。

Fight To Fame BMSは、グローバルの人材に道を切り開き、財産の奇跡を生み出そうとしていると主張している。プーチン大統領によるロシアのボクサーを授与されたボクシングチャンピオンであるRoy Jones Jr.氏、ブラジルの柔術チャンピオンであるRigan Machado氏、南アフリカのボクシングチャンピオンであるChris Van Heerden氏、ベトナムのキングオブファイターズ、ハリウッドのアクションスターであるCung Le氏など、合計6人のボクシングチャンピオンと連携した。彼らは次々とFight To Fameグローバルボクシングアンバサダーになった。Roy Jones Jr.氏が言ったように、「私はこれらの若いチャンピオンのメンターと友達になることを楽しみにしている」。また、Rigan Machado氏は、「Fight To Fameの包括的ビジネスモデルは、世界的に金持ちになる経験を生み出し、より多くの世界のつながりを実現し、平和と繁栄のための前向きな力となることができる」とのように信じている。

Fight To Fame BMS映画コミッショナー、有名なハリウッド映画プロデューサー、監督であるPhillipeによると、アジア、ラテンアメリカ、アフリカなどの国と地域で、Fight To Fame BMSに主催されるイベント、アクションスターリアリティショー、コマーシャル映画への投資というモデルは、リアリティショーで数多くの特別貢献賞を受賞した。そしてペルーなどの一部の国では、Fight To Fame BMSに国内フランチャイズライセンスを許可された。

Fight to Fameの拡大が鈍化する兆はなく、彼らの計画は野心的で説得力がある。 Fight to Fameはグローバルイベントを統合するか? BMSモデルはどのようにしてスター育成の夢工場に変わるのだろうか? FFトークンはどのような富の奇跡を生み出するか?

https://tinyurl.com/yd8b7qwv

メディアの連絡先:
メディア連絡先
会社名: fight to fame
担当者: Willy Mann•Poch
ウェブサイト: http://fight2fame.com/
メール: service@fighttofame.com



Copyright 2020 JCN Newswire. All rights reserved. www.jcnnewswire.com Via JCN Newswire https://ift.tt/2pbRN02

Greenbriar to Seek Uplift to the Nasdaq Global Market

Newport Beach, California, Jun 1, 2020 - (ACN Newswire) - Greenbriar Capital Corp. (TSXV: GRB) (OTC: GEBRF) ("Greenbriar") is pleased to announce that Greenbriar is seeking to obtain a full listing on the world class NASDAQ Global Market Select. Conditions to list on the NASDAQ Global Market Select are a minimum US $4.00 share price, at least US $4 Million in net current assets plus the appropriate registration and exemption filings with the US Securities and Exchange Commission. Greenbriar is currently conducting internal non-deal road shows via conference calls with our own 53,000 investors and followers. The Greenbriar story is resonating with a broad spectrum of investors.

Greenbriar is moving ahead to construct the sophisticated 160MWdc/80MWac Montalva solar project in Puerto Rico, which will become the largest solar facility in the Caribbean once completed. Greenbriar is very confident the project will expand to 320MWdc/160MWac in the very near future. A sizeable electro-chemical storage facility as part of the solar field will enable 24/7 dispatch which is unique in ultra-large scale solar generation facilities. Montalva will provide Puerto Rican citizens with lower-cost, clean and reliable electricity and replace some of the current expensive and dirty oil generation.

The company is proudly building the project with the China Machinery Engineering Corporation (CMEC), a leading world class premier construction and engineering company, forming part of the USD $40 Billion China National Machinery Industry Corporation (Sinomach) group of companies.

Greenbriar has been informed by its legal counsel Luis Baco, JD, LLM, that the PREPA Governing Board has approved our project and contract this past Thursday May 28 and the contract has been presented to the US FOMB (US Federal Oversight Management Board) for final approval. In 2018 the US FOMB already recommended Montalva to be deemed a critical project to rebuild Puerto Rico. Montalva will provide over 900 construction jobs, an increased tax base and hundreds of millions of dollars of private funds invested to rebuild a new and resilient electrical grid. Greenbriar is proud of this contribution and its existing 12 year non-stop commitment in Puerto Rico.

About Greenbriar Capital Corp

Greenbriar is a leading developer of renewable energy and sustainable real estate. With long-term, high impact, contracted sales agreements in key project locations and led by a successful, industry-recognized operating and development team, Greenbriar targets deep valued assets directed at accretive shareholder value. Greenbriar and its advisors have closed over $180 Billion in renewable energy projects since 2003 with previous companies.

ON BEHALF OF THE BOARD OF DIRECTORS
"Jeff Ciachurski"
Jeffrey J. Ciachurski
Chief Executive Officer and Director

The TSX Venture Exchange has not reviewed and does not accept responsibility for the accuracy or adequacy of this release. Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. This press release may contain forward-looking statements. All statements, other than statements of historical fact, constitute "forward-looking statements" and include any information that addresses activities, events or developments that the Company believes, expects or anticipates will or may occur in the future including the Company's strategy, plans or future financial or operating performance and other statements that express management's expectations or estimates of future performance.

Copyright 2020 ACN Newswire. All rights reserved. www.acnnewswire.com

source http://www.acnnewswire.com/press-release/english/59319/

マツダ、人事異動を発表

HIROSHIMA, Japan, Jun 1, 2020 - (JCN Newswire) - マツダ株式会社は2020年6月1日付で下記の通り人事異動を行います。

部長職以上
新/旧/氏名
商品本部主査/<出向>(株)マツダE&T 常務執行役員/小澤 裕史
<出向>(株)マツダプロセシング中国顧問/CS部品部主幹/林 洋平
<出向>(株)マツダE&T 執行役員/ボデー開発部マネージャー/吉田 元喜

本リリースの詳細は下記をご参照ください。
https://newsroom.mazda.com/ja/publicity/release/2020/202006/200601a.html

概要:マツダ株式会社

詳細は www.mazda.co.jp をご覧ください。



Copyright 2020 JCN Newswire. All rights reserved. www.jcnnewswire.com Via JCN Newswire https://ift.tt/2pbRN02

APOLLO FUTURE MOBILITY GROUP Announces 2020 Interim Results

HONG KONG, Jun 1, 2020 - (ACN Newswire) - Apollo Future Mobility Group Limited ("AFMG", the "Company", HKEx stock code: 860.HK; and together with its subsidiaries, the "Group") announced its first interim results for the six months ended 31 March 2020 (the "Period") since its change in strategic position to become one of the world's leading full-service mobility solutions provider.

Despite being faced with numerous macro challenges during the Period, the Company had successfully aligned its focus to the mobility technology solutions market and made progressive changes to the company structure. The Group recorded a moderate revenue of HK$256.9 million amidst drastic economic downturn caused by the COVID-19 outbreak, in comparison to the 2019 interim results of HK$281.1 million. The Group's loss attributable to owners of the Company for the Period was HK$203.4 million, which was mainly attributable to the fair value losses on financial assets and investment properties caused by the global market declined as well as the impairment of goodwill due to the termination of its legacy businesses. The board of directors are confident of the Group's outlook after all acquisition plans, thus will retain the capital for future developments and in creating shareholder value in long-term.

Successful Completion of Apollo Acquisition and Rebranding

The Group's English name was changed and registered as "Apollo Future Mobility Group Limited" on 13 March 2020 subsequent to the completion of the acquisition of Sino Partner Global Limited ("Apollo"). This transformation marks the Company's determination in capturing new potential business opportunities and future developments in the mobility industry, and will better reflect the Group's business strategies and expansion in new energy vehicle ("NEV(s)") solutions and services.

Additionally, to further strengthen its ability to provide cutting edge technological solutions, the Group announced in October 2019 the proposed acquisition of Ideenion Automobil AG, a German mobility solutions provider principally engaged in the design, development and prototyping of internal combustion engine vehicles and NEVs (dubbed "Project Ideenion"). With its advanced design and engineering expertise, Project Ideenion will further enhance the Group's ability to provide high-end technological solutions to customers upon the acquisition's targeted completion in this year.

Following the acquisition of Apollo, the Group rebranded and focuses its business development on two pillars, which are Apollo Automobil and Apollo Advanced Technologies (AAT). In addition to the development and sales of hypercars and its cross-branding licensing business under the "Apollo" brand, the Group provides one-stop turnkey mobility technology solutions by integrating Apollo Automobil's and the Group's existing electric vehicle technologies, from ideation, design, modeling, engineering, simulation, prototype production, actual testing, to the delivery of pre-production prototypes to customers, striving to provide the global mobility market with a seamless and comprehensive solution platform.

Steadfast Blueprint for Business Development

During the Period, and prior to the completion of the Apollo acquisition, Apollo delivered two (2) of its flagship hypercar model, the Apollo Intensa Emozione (the "Apollo IE"). Delivery ceremonies took place in Miami, USA and Kyoto, Japan in late 2019. The delivery of the first two (2) Apollo IEs received worldwide media coverage. The Group is now working diligently on delivering the remaining eight (8) Apollo IE by 2021 and creating the next generation consumer products. Both Apollo and GLM, subsidiaries of the Company, are in the process of designing and developing next generation self branded vehicles. The Group is confident in its robust product pipeline and the future of its mobility business.

Regarding the mobility solutions segment, in response to national policies for rapid development of electric vehicle ("EV(s)"), the Group grasped new opportunity to accelerate its business expansion plan in China's NEV market by establishing a joint venture company (the "JV Company") with Jiangsu Jemmell New Energy Automobile Company Limited (a related company of Jiangsu Jinpeng Group Company, one of the PRC's largest EV tricycle manufacturers) during the Period. The JV Company will engage primarily in the design, research and development, and production of NEVs under the "GLM" brand and related automobile parts, along with related technical support and after-sales services. The EVs produced will be targeting the younger generations to meet the market demands in the PRC, Japan, and Southeast Asia.

Significant Breakthrough in Technological Advancement

GLM made significant breakthrough in technological advancement by cooperating with ROHM Co., Ltd ("ROHM"), a leading semiconductor and electronic component manufacturer in Japan, in co-developing 800V silicon carbide ("SiC") dual inverters which can greatly reduce the charging time of EVs. To maintain its competitive edge, not only will the Group continue to accelerate its progress for the launch of the disruptive 800V SiC dual inverter, but also consider cooperation opportunities with motor manufacturers to market the new 800V SiC dual inverter, coupled with the battery management system with solid state battery and the motor manufacturers' own motors as a complete package to international OEMs. The Group is also exploring a licensing model to propel a new revenue stream in the near future and to better focus on research & development and innovation.

Furthermore, the Group is in the process of developing its own vehicle control unit, which is used to control all functions of the vehicle. The Group will continue to make unremitting efforts to optimize its core technologies and strengthen its capabilities of providing state-of-the-art solutions.

Propel New Revenue Source with Licensing Model

The Group has been actively exploring different sources of income leveraging on its renowned brand name and proprietary technologies. Apart from exploring to license its newly developed dual inverters, in May 2020, Apollo entered into the License Agreement with De Tomaso Automobili Limited ("De Tomaso", an Italian car-manufacturing company focused on making sport cars) whereby De Tomaso is granted the rights to use the new vehicular platform designed and developed by Apollo ("the Platform") in their "De Tomaso" branded vehicles worldwide at a minimum aggregate license fee of US$10,000,000 (equivalent to approximately HK$78,000,000) with a term of three years. The Group expects that the first-class Platform will also appeal to other automobile OEMs and hence continue to generate more revenue to the Group under the licensing model. It will continue to explore similar collaborations in the future to fulfill its mobility strategy.

"The first half of FY2020 had been a challenging period for businesses across all sectors. Despite the complications, our Group was fortunate to be comparably less affected as others,"

"The full transformation to an integrated mobility technology provider and the COVID-19 pandemic put slight stresses to our books temporarily. However, in light of favorable policies such as incentives for the deployment of charging infrastructure and technological advancement, the rapid growth momentum of the global mobility engineering market is expected to grow with unprecedented opportunities. It is expected that the demand for mobility solutions will increase in the long-term as OEMs look for significant cost reductions while outsourcing offers considerable ongoing savings and valuable innovations." comments Mr. Ho King Fung, Eric, Chairman of Apollo Future Mobility Group.

Mr. Ho continues, "Our Group is confident that as the PRC gradually opens its automobile market to foreign automobile companies, the Group will be able to partake with our proprietary technologies accumulated through recent acquisitions and strategic cooperations. Along with our recent exciting progress with De Tomaso, we are set to be a pioneer in the mobility technology solutions market, and seek to further expand our footprint across the globe in the coming years."

About Apollo Future Mobility Group Limited
Apollo Future Mobility Group Limited ("AFMG", stock code: 860.HK) is a leading integrated mobility technology solution provider with proprietary technologies that are disruptive to mobility industry. It is determined to build a world-leading one-stop service platform for "future mobility" through the integration of globally advanced mobility assets and networks.

After completing the acquisition of 86.06% of Apollo Automobil, a European high-performance hypercar developer, in March 2020, the Group rebranded as "Apollo Future Mobility Group", focusing its business development on two pillars, which are Apollo Automobil and Apollo Advanced Technologies (AAT). In addition to the development and sales of hypercars and its cross-branding licensing business under the "Apollo" brand, the Group provides one-stop turnkey solutions by integrating Apollo Automobil and the Group's existing electric vehicle technologies, from ideation, design, modeling, engineering, simulation, prototype production, actual testing, to the delivery of pre-production prototypes to customers, striving to provide the global mobility market with a seamless and comprehensive solution platform.

The Group's subsidiaries include Apollo Automobil, a high-performance European hypercar developer, and GLM Co. Ltd, the first electric vehicle developer in Japan. In addition, the Group has also expanded its mobility technologies by investing in Divergent Technologies, Inc., the world's first 3D metal printing automotive manufacturing platform, and EV Power, a leading electric vehicle charging solutions provider.

For more details, please visit http://www.apollofmg.com/


Copyright 2020 ACN Newswire. All rights reserved. www.acnnewswire.com

source http://www.acnnewswire.com/press-release/english/59313/

デンソーとセルトン、施設園芸ソリューションを提供する販売会社を設立

TOKYO, Jun 1, 2020 - (JCN Newswire) - 株式会社デンソー(本社:愛知県刈谷市、社長:有馬 浩二)とセルトングループ(本社:オランダ、社長:Hein van der Sande)は、施設園芸ソリューションを提供する販売会社「株式会社デンソーアグリテックソリューションズ(本社:東京都港区、社長:清水 修)」を2020年5月29日に設立しました。

今回設立した「株式会社デンソーアグリテックソリューションズ」では、デンソーのプロファームTキューブ*をはじめとする施設園芸製品に加え、セルトンの持つ世界最先端の施設園芸製品、今後両社で共同開発する次世代施設園芸製品、お客様のご要望に合わせた栽培コンサルティング、およびアフターサービスをパッケージ化し販売していく予定です。また、新会社は、豊田通商株式会社との協業を通じ施設園芸製品を利用して生産される農産物の販売支援を行います。

デンソーは、セルトンと2020年3月に資本提携を行い、デンソーの自動車分野で培った幅広い技術と、セルトンの施設園芸分野での先進技術を掛け合わせることで、世界各国の多様なニーズに合わせた農業ソリューションの提供に向けて協業を開始しました。このたび、両社で販売会社を設立し、日本をはじめとするアジア地域を中心とした販売体制強化を進め、施設園芸ソリューションをグローバルに展開していきます。

デンソーは、次世代施設園芸技術をグローバルに展開することで、持続可能な農業生産に貢献していくと共に、農食分野への新たな価値の提供を目指し、フードバリューチェーンビジネスの構築に取り組んでいきます。

本リリースの詳細は下記をご参照ください。
https://www.denso.com/jp/ja/news/news-releases/2020/20200601-01/

概要:株式会社デンソー

詳細は https://www.denso.com/jp/ja/ をご覧ください。



Copyright 2020 JCN Newswire. All rights reserved. www.jcnnewswire.com Via JCN Newswire https://ift.tt/2pbRN02

富士通、米Scaled Agile, Inc.とパートナーシップ契約を締結し、エンタープライズ領域における大規模アジャイルを推進

TOKYO, Jun 1, 2020 - (JCN Newswire) - 当社はこのたび、大規模システム開発へのアジャイル適用ニーズに対応するため、Scaled Agile, Inc.(本社:米国コロラド州、CEO:Chris James、以下、SAI)と、パートナーシップ契約「Gold Transformation Partner」を締結することで合意しました。今後、日本を皮切りに、グローバルに順次サービス提供を開始します。

近年、デジタル技術の進展に伴い、エンタープライズ市場を取り巻く環境は急激かつ大幅な変化が起き、それを支えるシステムも俊敏かつ柔軟に対応することが求められています。これまでは、比較的小規模かつシンプルなフロントシステムを中心にアジャイル開発が適用されてきましたが、市場の劇的な変化に俊敏に対応するために、金融業や製造業を中心に大規模かつ複雑な基幹システムを含むエンタープライズ領域における大規模アジャイルの必要性が高まっています。

本契約は、SAIが開発した大規模アジャイル開発のフレームワークであるScaled Agile Framework(R)(注1、以下、SAFe)の認定コンサルタントが5名以上在籍し、お客様のビジネス変革に向けてSAFe導入を変革パートナーとして支援できる企業のみが取得できるという特徴があります。また、Gold Transformation Partnerとなることで、SAIのSAFeスペシャリストによるコンサルティングサポートを受けることができるため、より高度な導入支援をお客様に提供することが可能となります。本契約に基づき、当社はこれまで培ってきた基幹系システムにおける実践知とSAFeを融合させた、大規模アジャイル適用サービスをお客様向けに提供します。また、2020年9月よりSAFeの教育プログラムをお客様やパートナー企業へ提供することで、大規模アジャイルの普及を図り、お客様のデジタルトランスフォーメーションを支援していきます。

Scaled Agile, Inc. チーフ・エグゼクティブ・オフィサー Chris James氏のコメント
富士通が、新たにGold Transformation PartnerとしてScaled Agileパートナープログラムに参画することを歓迎します。今後より多くの日本企業が、デジタルトランスフォーメーションの成功に向けた重要施策をビジネスアジリティの獲得であると認識し、その目標達成のためにSAFeのリーンアジャイル・プラクティスを活用していくことを期待しています。また、SAFeを自社のソリューション提案に取り込むことで、富士通は日本企業がグローバルのマーケットでよりアジャイルに、かつインダストリーの中で高い競争力を持つための強力な支援を行うことができるパートナーだと確信しています。

本リリースの詳細は下記をご参照ください。
https://pr.fujitsu.com/jp/news/2020/06/1.html

概要:富士通株式会社

詳細は http://jp.fujitsu.com/ をご覧ください。



Copyright 2020 JCN Newswire. All rights reserved. www.jcnnewswire.com Via JCN Newswire https://ift.tt/2pbRN02

After Scientific Breakthrough: Digid Seeks FDA Approval for Its Rapid Corona Antigen Test

Mainz, Germany, May 30, 2020 - (JCN Newswire) - At the high-security laboratory of the Helmholtz Centre for Infection Research (HZI) in Braunschweig, Germany, the revolutionary Cantisense(TM)At the high-security laboratory of the Helmholtz Centre for Infection Research (HZI) in Braunschweig, Germany, the revolutionary Cantisense(TM) technology of the German health technology company Digital Diagnostics AG was used for the first time to successfully detect SARS-CoV-2 viruses in high measuring accuracy in test liquids. technology of the German health technology company Digital Diagnostics AG was used for the first time to successfully detect SARS-CoV-2 viruses in high measuring accuracy in test liquids.

In contrast to PCR testing, the new test provides a clear electronic "YES" or "NO" information within a few minutes, saving precious time in the diagnosis. What's more, the Digid Cantisense(TM) SARS-CoV-2 Test directly detects the presence of the virus while other rapid tests only recognize antibodies.

Konstantin Kloppstech, CTO at Digital Diagnostics, says: "Recent test series at the HZI high-security laboratory have shown that SARS-CoV-2 viruses can be detected directly using our Cantisense technology and without the need for PCR or further sample processing. This is a scientific breakthrough. We have coated cantilevers with a capture layer of highly specific monoclonal antibodies, which can reliably bind SARS-CO-2 viruses in the test fluid."

Constantin von Gersdorff, CEO of Digital Diagnostics, said: "The next step will be to initiate clinical studies with patient samples. To this end, we have already established international collaborations with leading hospitals."

With Digid's test kit, the measurement results are transmitted wirelessly from a sensor hub to a mobile device. By connecting to a secure analytics platform, the sensor data can be augmented with further data and processed anonymously for research and diagnostic applications.

Due to its measurement speed and the highly reliable results, the test is particularly suitable to support the containment of the current SARS-CoV-2 pandemic. The test offers the possibility of simple and rapid testing of patients and medical staff as an alternative to laboratory tests and enables reliable identification of infected persons within minutes. The possible areas of application therefore also include screening for access control at airports and railway stations, hospitals and specially protected areas (such as retirement homes) as well as for companies who want to ensure that their production runs smoothly and safely.

Digital Diagnostics has applied for approval of the Digid Cantisense(TM) SARS-CoV-2 Test by the US Food and Drug Administration (FDA). Digid aims to provide millions of units by July 2020. A further scaling of capacities is planned in the short term. The experts at Digital Diagnostics are also working at full speed to further develop the technology and to adapt the point-of-care testing procedure for use by consumers at home.

Press contact
Thomas Huber
semanticom GmbH
+49 30 275 80 81 11
digid-pr@semanticom.eu

Related Images
https://www.newsfilecorp.com/redirect/waAZCxPR
Point-of-care test kit: sensor hub, biosensor, mobile device
With digid's point-of-care solution, the measurement results are transmitted wirelessly from a sensor hub to a mobile device. By connecting to a secure analytics platform, the numerous sensor data can be augmented with further data and processed anonymously for research and diagnostic applications. (prototype/copyright: Digital Diagnostics AG)

Related Links
https://digid.com/en/



Copyright 2020 JCN Newswire. All rights reserved. www.jcnnewswire.com Via JCN Newswire https://ift.tt/2pbRN02

New Study Underscores How Heated Tobacco Products Are Disrupting the Cigarette Industry

MANILA, May 31, 2020 - (JCN Newswire) - A new study shows that the entry of heated tobacco products (HTPs) triggered a remarkable reduction in combustible cigarettes sales in Japan. "The decline in smoking rates among adults in Japan is astoundingly impressive when you realize that this has only come about rapidly with the introduction of HTPs," said Nancy Loucas, Executive Director of the Coalition of Asia-Pacific Tobacco Harm Reduction Advocates (CAPHRA).

Canadian and American researchers looked at how trends in the sale of cigarettes in Japan between 2011 and 2019 correspond to the sales of HTPs that were introduced into the Japanese market in late 2015. Using data from the Tobacco Institute of Japan and Philip Morris International (PMI), the researchers concluded that the accelerated five-fold decline in cigarette only sales in Japan since 2016 corresponds to the introduction and growth in the sales of HTPs. Cigarette sales in Japan were declining slowly and steadily before HTPs were introduced in 2015.

Entitled "What Is Accounting for the Rapid Decline in Cigarette Sales in Japan?", the study was published on May 20, 2020 in the peer-reviewed open access scientific journal International Journal of Environmental Research and Public Health.

HTPs are smoke-free devices that heat, instead of burn, specially-designed tobacco units to release a flavorful nicotine-containing tobacco vapor. As tobacco is not burned, the levels of harmful chemicals produced by HNB products are significantly lower compared to combustible cigarette smoke. The most popular HTP brand is IQOS, a product of PMI.

Consumers' interest and the regulatory environment shape markets, according to Professor David T. Sweanor of the Faculty of Law of University of Ottawa, one of the study's authors. He explained that Japanese regulations precluded alternatives to combustible cigarettes, such as nicotine-containing vaping products. However, HTPs generated huge interest among smokers in Japan. "As more [smokers] adopted the alternative, they helped speed switching by others. I think this gives us an indication of just how much more rapidly countries could reduce cigarette use if there were many different low-risk alternatives available and policies and public education campaigns facilitated a widespread move away from [combustible] cigarettes."

Prof. Sweanor believes Japan is a success story in tobacco harm reduction.

"We have seen the most rapid decline in cigarette sales ever witnessed in a major market. A third of the cigarette market was gone in a remarkably short period of time, and this was accomplished with a non-coercive measure. People who smoke cigarettes were simply provided with a viable alternative."

Governments in the Asia Pacific region that seek to ban or limit the access of smokers to HTPs and other safer nicotine alternatives should look to Sweden which for decades has promoted the shift to low-risk non-combustible alternatives to cigarettes, said Prof. Sweanor. "Now we have evidence that a range of low-risk products can help us rapidly achieve the smoking rate targets of the World Health Organization's Sustainable Development Goals. To seek to ban or limit access to such products protects the cigarette industry rather than public health."

Commenting on the future of smokers in Asia Pacific where HTPs will soon be available, Prof. Sweanor stressed that policies should empower people to take control of their health. "Ensuring that a range of low-risk alternatives are not only on the market but have regulatory and tax advantages over cigarettes has the potential to transform public health. We have long known that people smoke for nicotine but die from the smoke. Cigarette smoking is a public health catastrophe that can be massively reduced through science and technology if policies can be oriented toward replacing rather than protecting the cigarette business."

The publication of the new study is timely as it comes on the heels of the celebration of World Vape Day on May 30, 2020. Observed a day before World No Tobacco Day, World Vaping Day aims to raise awareness on e-cigarettes or vapes and encourage smokers who are unable to quit on their own or with currently available smoking cessation tools to switch to safer nicotine products.

"Safer nicotine products, such as e-cigarettes and heated tobacco products, are the most disruptive influence on smoking in decades. These are the innovations that have the potential to save millions of lives in the Asia Pacific region as well as globally," added Nancy Loucas.

According to Loucas, the most popular form of safer nicotine products in northern Asia are HTPs. Like Japan, Korea has shown similar sales and uptake of HTPs, with corresponding declines in combustible tobacco use. These data show that the substitution of combustible tobacco with reduced-risk products has the potential to be a highly effective tobacco harm reduction strategy, she explained. "So, it is very disheartening that countries in Asia Pacific, like Korea and the Philippines, are looking to either ban and/or reduce access and choice of all forms of tobacco harm reduced products for their smoking citizens."

"Japan's success in reducing smoking prevalence through HTPs should be a wakeup call to local policymakers. Quit or die aren't the only choices for smokers," said Peter Paul Dator, president of The Vapers Philippines.

"This new study lends further credence to adopting tobacco control policies based on a harm reduction model," said Stephanie Thuesen, Director of Stakeholder Engagement at The Progressive Public Health Alliance in Australia.

"Policymakers in Thailand, which has been ranked the worst country in the world to be in if you are a vaper, should listen to Prof. Sweanor. Banning or limiting access to safer nicotine products only serve to protect the cigarette industry rather than public health," said Asa Ace Saligupta who runs the ECST.

About CAPHRA

The Coalition of Asia Pacific Tobacco Harm Reduction Advocates (CAPHRA) is an alliance of consumer organizations from Australia, Hong Kong, India, Indonesia, Malaysia, New Zealand, the Philippines, South Korea, Taiwan and Thailand that aims to educate, advocate and represent the right of adult alternative nicotine consumers to access and use of products that reduce harm from tobacco use.

MEDIA CONTACT: Jena Fetalino (63)9178150324 jena@jfprc.com

Prof. David Sweanor, one of the study's authors
"We have seen the most rapid decline in cigarette sales ever witnessed in a major market."

Related Links
International journal of Environmental Research and Public Health https://www.newsfilecorp.com/redirect/naABf5xr



Copyright 2020 JCN Newswire. All rights reserved. www.jcnnewswire.com Via JCN Newswire https://ift.tt/2pbRN02

JCB signs a Strategic Partnership Agreement with TECHFUND for Joint Research on Sustainable Payment System Using Blockchain

TOKYO, Jun 1, 2020 - (ACN Newswire) - JCB Co., Ltd., a global payment network and a leading issuer and acquirer in Japan, and TECHFUND Inc., a technology accelerator promoting innovation in startups and leading companies, have signed a strategic partnership agreement to jointly research the construction of a sustainable payment system using blockchain. Based on TECHFUND's blockchain technologies such as STO (Security Token Offering)*1 and staking*2, JCB and TECHFUND jointly research the payment platform that will contribute to solving various issues in the payment field.




*1 STO: A method of raising funds through tokenized securities issued on the blockchain.
*2 Staking: Earning a reward by continuously holding crypto currencies and contributing to the stability of the system.

About JCB

JCB is a global payment brand and a leading credit card issuer and acquirer in Japan. JCB launched its card business in Japan in 1961 and began expanding worldwide in 1981. Its acceptance network includes about 34 million merchants as well as cash advance locations around the world. JCB cards are now issued in 24 countries and territories, with more than 140 million cardmembers. As part of its international growth strategy, JCB has formed alliances with hundreds of leading banks and financial institutions globally to increase merchant coverage and cardmember base. As a comprehensive payment solution provider, JCB commits to providing responsive and high-quality service and products to all customers worldwide. For more information, please visit https://www.global.jcb/en/

About TECHFUND

TECHFUND, a TECHNOLOGY ACCELERATOR, was launched on October 9, 2014 with a vision, "BE AN ENTREPRENEUR". As the world's first technology accelerator to support startups by investing "technology" instead of money, we have been involved in more than 300 teams of mentoring and due diligence, and have invested in 10 companies. At the same time, we provide an intrapreneur program, "ACCEL PROGRAM for BIZ", for major companies and contributed to 30 leading companies' innovations. We also develop scoring algorithms to assess the growth potential of startups and new businesses. TECHFUND is currently focusing on supporting blockchain and STO projects, as well as developing and providing ACCEL BaaS (Blockchain as a Service) to "accelerate" the development of blockchain applications for startups and enterprises. Among the supported startups is EtherSecurity, a company in the staking business.

Contact
JCB
Kumiko Kida, Ayaka Nakajima
Corporate Communications
Phone: +81-3-5778-8353
Email: jcb-pr@jcb.co.jp

TECHFUND Inc.
Peaske.Kawahara
Communication Strategy Div
Email: press@techfund.jp (Cc: peaske@techfund.jp)

Copyright 2020 ACN Newswire. All rights reserved. www.acnnewswire.com

source http://www.acnnewswire.com/press-release/english/59292/

5/30/20

New Study Underscores How Heated Tobacco Products Are Disrupting the Cigarette Industry

MANILA, May 31, 2020 - (ACN Newswire) - A new study shows that the entry of heated tobacco products (HTPs) triggered a remarkable reduction in combustible cigarettes sales in Japan. "The decline in smoking rates among adults in Japan is astoundingly impressive when you realize that this has only come about rapidly with the introduction of HTPs," said Nancy Loucas, Executive Director of the Coalition of Asia-Pacific Tobacco Harm Reduction Advocates (CAPHRA).


Prof. David Sweanor, one of the study's authors


Canadian and American researchers looked at how trends in the sale of cigarettes in Japan between 2011 and 2019 correspond to the sales of HTPs that were introduced into the Japanese market in late 2015. Using data from the Tobacco Institute of Japan and Philip Morris International (PMI), the researchers concluded that the accelerated five-fold decline in cigarette only sales in Japan since 2016 corresponds to the introduction and growth in the sales of HTPs. Cigarette sales in Japan were declining slowly and steadily before HTPs were introduced in 2015.

Entitled "What Is Accounting for the Rapid Decline in Cigarette Sales in Japan?", the study was published on May 20, 2020 in the peer-reviewed open access scientific journal International Journal of Environmental Research and Public Health.

HTPs are smoke-free devices that heat, instead of burn, specially-designed tobacco units to release a flavorful nicotine-containing tobacco vapor. As tobacco is not burned, the levels of harmful chemicals produced by HNB products are significantly lower compared to combustible cigarette smoke. The most popular HTP brand is IQOS, a product of PMI.

Consumers' interest and the regulatory environment shape markets, according to Professor David T. Sweanor of the Faculty of Law of University of Ottawa, one of the study's authors. He explained that Japanese regulations precluded alternatives to combustible cigarettes, such as nicotine-containing vaping products. However, HTPs generated huge interest among smokers in Japan. "As more [smokers] adopted the alternative, they helped speed switching by others. I think this gives us an indication of just how much more rapidly countries could reduce cigarette use if there were many different low-risk alternatives available and policies and public education campaigns facilitated a widespread move away from [combustible] cigarettes."

Prof. Sweanor believes Japan is a success story in tobacco harm reduction.

"We have seen the most rapid decline in cigarette sales ever witnessed in a major market. A third of the cigarette market was gone in a remarkably short period of time, and this was accomplished with a non-coercive measure. People who smoke cigarettes were simply provided with a viable alternative."

Governments in the Asia Pacific region that seek to ban or limit the access of smokers to HTPs and other safer nicotine alternatives should look to Sweden which for decades has promoted the shift to low-risk non-combustible alternatives to cigarettes, said Prof. Sweanor. "Now we have evidence that a range of low-risk products can help us rapidly achieve the smoking rate targets of the World Health Organization's Sustainable Development Goals. To seek to ban or limit access to such products protects the cigarette industry rather than public health."

Commenting on the future of smokers in Asia Pacific where HTPs will soon be available, Prof. Sweanor stressed that policies should empower people to take control of their health. "Ensuring that a range of low-risk alternatives are not only on the market but have regulatory and tax advantages over cigarettes has the potential to transform public health. We have long known that people smoke for nicotine but die from the smoke. Cigarette smoking is a public health catastrophe that can be massively reduced through science and technology if policies can be oriented toward replacing rather than protecting the cigarette business."

The publication of the new study is timely as it comes on the heels of the celebration of World Vape Day on May 30, 2020. Observed a day before World No Tobacco Day, World Vaping Day aims to raise awareness on e-cigarettes or vapes and encourage smokers who are unable to quit on their own or with currently available smoking cessation tools to switch to safer nicotine products.

"Safer nicotine products, such as e-cigarettes and heated tobacco products, are the most disruptive influence on smoking in decades. These are the innovations that have the potential to save millions of lives in the Asia Pacific region as well as globally," added Nancy Loucas.

According to Loucas, the most popular form of safer nicotine products in northern Asia are HTPs. Like Japan, Korea has shown similar sales and uptake of HTPs, with corresponding declines in combustible tobacco use. These data show that the substitution of combustible tobacco with reduced-risk products has the potential to be a highly effective tobacco harm reduction strategy, she explained. "So, it is very disheartening that countries in Asia Pacific, like Korea and the Philippines, are looking to either ban and/or reduce access and choice of all forms of tobacco harm reduced products for their smoking citizens."

"Japan's success in reducing smoking prevalence through HTPs should be a wakeup call to local policymakers. Quit or die aren't the only choices for smokers," said Peter Paul Dator, president of The Vapers Philippines.

"This new study lends further credence to adopting tobacco control policies based on a harm reduction model," said Stephanie Thuesen, Director of Stakeholder Engagement at The Progressive Public Health Alliance in Australia.

"Policymakers in Thailand, which has been ranked the worst country in the world to be in if you are a vaper, should listen to Prof. Sweanor. Banning or limiting access to safer nicotine products only serve to protect the cigarette industry rather than public health," said Asa Ace Saligupta who runs the ECST.

About CAPHRA

The Coalition of Asia Pacific Tobacco Harm Reduction Advocates (CAPHRA) is an alliance of consumer organizations from Australia, Hong Kong, India, Indonesia, Malaysia, New Zealand, the Philippines, South Korea, Taiwan and Thailand that aims to educate, advocate and represent the right of adult alternative nicotine consumers to access and use of products that reduce harm from tobacco use.

MEDIA CONTACT: Jena Fetalino (63)9178150324 jena@jfprc.com

Prof. David Sweanor, one of the study's authors
"We have seen the most rapid decline in cigarette sales ever witnessed in a major market."

Related Links
International journal of Environmental Research and Public Health https://www.newsfilecorp.com/redirect/naABf5xr

Copyright 2020 ACN Newswire. All rights reserved. www.acnnewswire.com

source http://www.acnnewswire.com/press-release/english/59304/

I-intern's co-founder Delysia Song: Guiding Chinese Students to a Future in America

SAN FRANCISCO, CA, May 30, 2020 - (JCN Newswire) - Acquiring the first years of work experience in the United States is forever an understated challenge for recent graduates as they enter the economy. It is a jaw-clenching situation that generally applies to us all yet proves to be unique from generation to generation - often slipping into hazy memory once the hurdle is cleared and thus little guidance ever seems to pass on. While some were able to acquire an entry-level job thanks to friends and family or internships through school, inking the first few lines of a resume can sometimes be an arduous process that relies on more than luck and simple favors. Imagine then how much more complicated things can become for international students from China, often lacking the same roots within the domestic market and already dealing with the disadvantages of assimilating into a new country - affected by politics, short on time, drawn out by geographic distances.




Shanghai native, Delysia Song lived through these difficulties herself and decided that others should not face them alone. Just as many in the internet era, Delysia sought to use technology as a game-changing tool. And like others of the entrepreneur generation, Delysia's approach to an age-old dilemma is to redefine the entire process to present a new solution. The result was Song's 2017 co-founding of the I-intern Career Consulting Group in San Francisco, a platform focused on providing students from abroad with internship opportunities and career advancement.

She elaborates, "The initial job search is a problem faced by every graduate, particularly if they lack experience. Traditionally, we looked at it as a step towards basic survival. Finding a job so you can feed yourself, manage to cover your expenses, and if you're lucky, provide for your family. It was rarely looked at as more than that. However, for those that undertook this journey of leaving their homes to study and live overseas, the job search isn't and shouldn't be that simple. If our goal was a better overall life and we sacrificed so much to achieve it, then the first step in our careers instead becomes a means of improving ourselves and realizing our potential. What used to be a scramble for a paycheck becomes more about gaining expertise and honing a vision of our future."

To that end, Delysia built upon the years she spent in Silicon Valley as a talent supplier and HR consultant for top companies that hire on both sides of the Pacific, such as Alibaba, Google, LinkedIn, Huawei among others. Noteworthy is a lesson Delysia quickly realized, that these employers do not simply try to fill ranks. Human resources development, empowerment, and the fostering of fresh ideas have led to countless breakthroughs in the respective organizations therefore tech employers, perhaps second to no other industry, see the value of newcomers. As the practice of venture capitalism and tech incubation suggests, if the idea is great enough even those with marginal experience are given valuable resources and powerful support. Delysia dubs this, "a progressive social and hiring trend."

Expanding her network from there, in particular as veterans shifted to their own startups and other growing companies in the San Francisco Bay area, Delysia saw demand for top talent increase and the need for a new kind of company.

I-intern, after all, took the premise of simple recruiting and staffing beyond the crude method of flooding candidates to job openings and vice versa, hoping that among all the shifting tides something useful washes ashore. Ms. Song instead looks at the students and soon-to-be graduates she helps as treasured participants, a relationship that can carry over into the employee/employer dynamic, "Talent, skillsets, and entrepreneurship itself are the result of long-term perseverance. The most important assets across all companies are ultimately the people. Products can be adjusted, the market constantly fluctuates, changes are inevitable. Only a unified team can successfully navigate these transitions. Therefore it only makes sense that we attach the rightful importance to each individual, we want to care for them just like family and be conscious of their needs, thoughts, and emotions. At I-intern we hope to pass along and contribute our own transition and job search experiences one-on-one."

In that regard, I-intern promotes a variety of methods to best gauge and understands candidates. Delysia explains, "The experience of studying abroad alone is not enough to find the best opportunities. We look instead to additional means like online coursework, career development planning, occupational and professional analysis, solutions for personal development, to provide a multi-dimensional diagnosis of an individual's abilities and interests. Only from there can we move into something as life-changing as their internship and job search."

And while I-intern is now successfully backed by CRCM, cooperates with top Chinese schools such as Nankai University and West Normal University, and is recognized as a valuable bridge for China-US campus recruiting, building from the ground up imparted many lessons on Delysia. She reflects, "There is certainly a lot you won't learn at university. It is not like homework where there's a given solution someone can refer you to. In a lot of ways there isn't ever a standard answer. Especially when you're a young team starting on something that's built from the ground up. For us, in the beginning, everything was done by hand. It can be imposing because entrepreneurism does not tolerate shortcomings. What helps is to accept that something as demanding as starting a company will require skills that are simply too much to learn by yourself. Building a team allows you to support each other, to collaborate, and face things together."

It is likely this shared knowledge that shaped I-intern's approach to caring customer service and business development. On a personal level, Delysia points to support from Kai-Fu Li, eminent AI specialist and tech pioneer, and others that imparted meaningful enlightenment along the way.

"When you are a young leader, it's difficult to gain recognition from most industries, from society as a whole. At some point people would call me 'the persistent Shanghai girl' and so I embraced that. Persistence plays a major factor in being acknowledged. Persistence is vital when you step away from the stable, comfortable path to go into the wild."

"Then I had the dream of I-intern becoming the most trusted institution in the field of career development and building it to be a full-scale platform for students. When you start moving into the issue of trust, there is no substitute for working with people one-on-one and proving yourself. You can't market trust, you build it through repeat customers and word of mouth. You prove to people that you'll be there for them."

This attitude is reaping rewards with I-intern doubling its sales figures in less than three years and literally, as Delysia was selected as one of the All American Chinese Youth Federation's "California Chinese 30 Under 30" in March.

Contact:
Delysia Song
delysia@iintern.com
I-intern Career Consulting Group
http://www.iintern.com





Copyright 2020 JCN Newswire. All rights reserved. www.jcnnewswire.com Via JCN Newswire https://ift.tt/2pbRN02

I-intern's co-founder Delysia Song: Guiding Chinese Students to a Future in America

SAN FRANCISCO, CA, May 30, 2020 - (ACN Newswire) - Acquiring the first years of work experience in the United States is forever an understated challenge for recent graduates as they enter the economy. It is a jaw-clenching situation that generally applies to us all yet proves to be unique from generation to generation - often slipping into hazy memory once the hurdle is cleared and thus little guidance ever seems to pass on. While some were able to acquire an entry-level job thanks to friends and family or internships through school, inking the first few lines of a resume can sometimes be an arduous process that relies on more than luck and simple favors. Imagine then how much more complicated things can become for international students from China, often lacking the same roots within the domestic market and already dealing with the disadvantages of assimilating into a new country - affected by politics, short on time, drawn out by geographic distances.




Shanghai native, Delysia Song lived through these difficulties herself and decided that others should not face them alone. Just as many in the internet era, Delysia sought to use technology as a game-changing tool. And like others of the entrepreneur generation, Delysia's approach to an age-old dilemma is to redefine the entire process to present a new solution. The result was Song's 2017 co-founding of the I-intern Career Consulting Group in San Francisco, a platform focused on providing students from abroad with internship opportunities and career advancement.

She elaborates, "The initial job search is a problem faced by every graduate, particularly if they lack experience. Traditionally, we looked at it as a step towards basic survival. Finding a job so you can feed yourself, manage to cover your expenses, and if you're lucky, provide for your family. It was rarely looked at as more than that. However, for those that undertook this journey of leaving their homes to study and live overseas, the job search isn't and shouldn't be that simple. If our goal was a better overall life and we sacrificed so much to achieve it, then the first step in our careers instead becomes a means of improving ourselves and realizing our potential. What used to be a scramble for a paycheck becomes more about gaining expertise and honing a vision of our future."

To that end, Delysia built upon the years she spent in Silicon Valley as a talent supplier and HR consultant for top companies that hire on both sides of the Pacific, such as Alibaba, Google, LinkedIn, Huawei among others. Noteworthy is a lesson Delysia quickly realized, that these employers do not simply try to fill ranks. Human resources development, empowerment, and the fostering of fresh ideas have led to countless breakthroughs in the respective organizations therefore tech employers, perhaps second to no other industry, see the value of newcomers. As the practice of venture capitalism and tech incubation suggests, if the idea is great enough even those with marginal experience are given valuable resources and powerful support. Delysia dubs this, "a progressive social and hiring trend."

Expanding her network from there, in particular as veterans shifted to their own startups and other growing companies in the San Francisco Bay area, Delysia saw demand for top talent increase and the need for a new kind of company.

I-intern, after all, took the premise of simple recruiting and staffing beyond the crude method of flooding candidates to job openings and vice versa, hoping that among all the shifting tides something useful washes ashore. Ms. Song instead looks at the students and soon-to-be graduates she helps as treasured participants, a relationship that can carry over into the employee/employer dynamic, "Talent, skillsets, and entrepreneurship itself are the result of long-term perseverance. The most important assets across all companies are ultimately the people. Products can be adjusted, the market constantly fluctuates, changes are inevitable. Only a unified team can successfully navigate these transitions. Therefore it only makes sense that we attach the rightful importance to each individual, we want to care for them just like family and be conscious of their needs, thoughts, and emotions. At I-intern we hope to pass along and contribute our own transition and job search experiences one-on-one."

In that regard, I-intern promotes a variety of methods to best gauge and understands candidates. Delysia explains, "The experience of studying abroad alone is not enough to find the best opportunities. We look instead to additional means like online coursework, career development planning, occupational and professional analysis, solutions for personal development, to provide a multi-dimensional diagnosis of an individual's abilities and interests. Only from there can we move into something as life-changing as their internship and job search."

And while I-intern is now successfully backed by CRCM, cooperates with top Chinese schools such as Nankai University and West Normal University, and is recognized as a valuable bridge for China-US campus recruiting, building from the ground up imparted many lessons on Delysia. She reflects, "There is certainly a lot you won't learn at university. It is not like homework where there's a given solution someone can refer you to. In a lot of ways there isn't ever a standard answer. Especially when you're a young team starting on something that's built from the ground up. For us, in the beginning, everything was done by hand. It can be imposing because entrepreneurism does not tolerate shortcomings. What helps is to accept that something as demanding as starting a company will require skills that are simply too much to learn by yourself. Building a team allows you to support each other, to collaborate, and face things together."

It is likely this shared knowledge that shaped I-intern's approach to caring customer service and business development. On a personal level, Delysia points to support from Kai-Fu Li, eminent AI specialist and tech pioneer, and others that imparted meaningful enlightenment along the way.

"When you are a young leader, it's difficult to gain recognition from most industries, from society as a whole. At some point people would call me 'the persistent Shanghai girl' and so I embraced that. Persistence plays a major factor in being acknowledged. Persistence is vital when you step away from the stable, comfortable path to go into the wild."

"Then I had the dream of I-intern becoming the most trusted institution in the field of career development and building it to be a full-scale platform for students. When you start moving into the issue of trust, there is no substitute for working with people one-on-one and proving yourself. You can't market trust, you build it through repeat customers and word of mouth. You prove to people that you'll be there for them."

This attitude is reaping rewards with I-intern doubling its sales figures in less than three years and literally, as Delysia was selected as one of the All American Chinese Youth Federation's "California Chinese 30 Under 30" in March.

Contact:
Delysia Song
delysia@iintern.com
I-intern Career Consulting Group
http://www.iintern.com


Copyright 2020 ACN Newswire. All rights reserved. www.acnnewswire.com

source http://www.acnnewswire.com/press-release/english/59301/

5/29/20

After Scientific Breakthrough: Digid Seeks FDA Approval for Its Rapid Corona Antigen Test

Mainz, Germany, May 30, 2020 - (ACN Newswire) - At the high-security laboratory of the Helmholtz Centre for Infection Research (HZI) in Braunschweig, Germany, the revolutionary Cantisense(TM) technology of the German health technology company Digital Diagnostics AG was used for the first time to successfully detect SARS-CoV-2 viruses in high measuring accuracy in test liquids.


Figure 1: Point-of-care test kit: sensor hub, biosensor, mobile device. With digid's point-of-care solution, the measurement results are transmitted wirelessly from a sensor hub to a mobile device. By connecting to a secure analytics platform, the numerous sensor data can be augmented with further data and processed anonymously for research and diagnostic applications. (prototype/copyright: Digital Diagnostics AG)


In contrast to PCR testing, the new test provides a clear electronic "YES" or "NO" information within a few minutes, saving precious time in the diagnosis. What's more, the Digid Cantisense(TM) SARS-CoV-2 Test directly detects the presence of the virus while other rapid tests only recognize antibodies.

Konstantin Kloppstech, CTO at Digital Diagnostics, says: "Recent test series at the HZI high-security laboratory have shown that SARS-CoV-2 viruses can be detected directly using our Cantisense technology and without the need for PCR or further sample processing. This is a scientific breakthrough. We have coated cantilevers with a capture layer of highly specific monoclonal antibodies, which can reliably bind SARS-CO-2 viruses in the test fluid."

Constantin von Gersdorff, CEO of Digital Diagnostics, said: "The next step will be to initiate clinical studies with patient samples. To this end, we have already established international collaborations with leading hospitals."

With Digid's test kit, the measurement results are transmitted wirelessly from a sensor hub to a mobile device. By connecting to a secure analytics platform, the sensor data can be augmented with further data and processed anonymously for research and diagnostic applications.

Due to its measurement speed and the highly reliable results, the test is particularly suitable to support the containment of the current SARS-CoV-2 pandemic. The test offers the possibility of simple and rapid testing of patients and medical staff as an alternative to laboratory tests and enables reliable identification of infected persons within minutes. The possible areas of application therefore also include screening for access control at airports and railway stations, hospitals and specially protected areas (such as retirement homes) as well as for companies who want to ensure that their production runs smoothly and safely.

Digital Diagnostics has applied for approval of the Digid Cantisense(TM) SARS-CoV-2 Test by the US Food and Drug Administration (FDA). Digid aims to provide millions of units by July 2020. A further scaling of capacities is planned in the short term. The experts at Digital Diagnostics are also working at full speed to further develop the technology and to adapt the point-of-care testing procedure for use by consumers at home.

Press contact
Thomas Huber
semanticom GmbH
+49 30 275 80 81 11
digid-pr@semanticom.eu

Related Images
https://www.newsfilecorp.com/redirect/waAZCxPR
Point-of-care test kit: sensor hub, biosensor, mobile device
With digid's point-of-care solution, the measurement results are transmitted wirelessly from a sensor hub to a mobile device. By connecting to a secure analytics platform, the numerous sensor data can be augmented with further data and processed anonymously for research and diagnostic applications. (prototype/copyright: Digital Diagnostics AG)

Related Links
https://digid.com/en/

Copyright 2020 ACN Newswire. All rights reserved. www.acnnewswire.com

source http://www.acnnewswire.com/press-release/english/59302/

アッヴィとエーザイ、ヒト型抗ヒトTNFαモノクローナル抗体「ヒュミラ(R)」について、化膿性汗腺炎の効能・効果に係る用法・用量の製造販売承認事項一部変更の承認取得のお知らせ

TOKYO, May 29, 2020 - (JCN Newswire) - アッヴィ合同会社(本社:東京都港区、社長:ジェームス・フェリシアーノ、以下「アッヴィ」)とエーザイ株式会社(本社:東京都、代表執行役 CEO:内藤晴夫、以下「エーザイ」)は、本日、ヒト型抗ヒト TNFα モノクローナル抗体「ヒュミラ(R)」(一般名:アダリムマブ<遺伝子組換え>、以下「ヒュミラ」)について、化膿性汗腺炎(Hidradenitis Suppurativa、以下「HS」)の初回投与 4 週間後以降の投与選択肢として、80mg 隔週投与追加による用法・用量の医薬品製造販売承認事項一部変更の承認を取得したことをお知らせします。

これまで、HS に対する用法・用量は、初回に 160mg を、初回投与 2 週間後に 80mg を皮下注射し、初回投与 4 週間後以降は、40mg を毎週投与するものでした。今回、40mg 毎週投与と同等の有効性および安全性を有する投与選択肢として 80mg 隔週投与が新たに追加されました。80mg 隔週投与は、従来の 40mg 毎週投与と比較し、投与回数の半減*と投与間隔の延長により、患者さんの注射による負担軽減につながる新たな選択肢として期待されます。

* ヒュミラ皮下注 80mg シリンジ 0.8mL、同 80mg ペン 0.8mL を使用した場合

今回の承認は、国内第 III 相試験(M15-573 試験)で得られたヒュミラの 80mg 隔週投与時の有効性および安全性の検討結果と薬物動態シミュレーションの成績に基づいています。国内第 III 相試験は、中等症から重症の日本人の HS 患者さんを対象に、ヒュミラの有効性および安全性を評価した多施設共同非盲検単一用量試験です。

ヒュミラは、2017 年に HS を予定する効能・効果として希少疾病医薬品に指定され、2019 年 2月 21 日に HS の効能・効果について国内で初めて承認を取得しました。現在、国内において HSの適応を有する薬剤はヒュミラのみです。

HS は思春期以降に多く発症し、疼痛を伴う慢性的な炎症性皮膚疾患です。炎症症状は、腋窩、鼠径部、乳房、臀部などに頻発し、主な症状は赤くはれ上がったおできのような症状ですが、進行すると結節、膿瘍、さらには瘻孔(ろうこう)の形成まで至り、繰り返すと病変部が肥厚し、瘢痕化(はんこんか)します 1。重症になると日常の活動が制限されることがあり、就業が困難になるケースもあります 2。日本における疫学については一定の解釈に至っていないものの 3、海外での有病率は 1%との報告があります 4 。疾患の認知度の低さや診断の困難さなどから、海外の報告では確定診断に至るまでの年数は平均 7 年で、乾癬など他の炎症性皮膚疾患よりも長く、受診回数が多いことも報告されています。

アッヴィとエーザイは、本適応を含む「ヒュミラ」の適正使用の推進と情報提供に努めることで、より多くの患者さんの QOL 向上に一層貢献してまいります。

ヒュミラについて

ヒト型抗ヒト TNFα モノクローナル抗体「ヒュミラ(R)」は、日本において「関節リウマチ (関節の構造的損傷の防止を含む)、化膿性汗腺炎、既存治療で効果不十分な尋常性乾癬・関節症性乾癬・膿疱性乾癬・強直性脊椎炎・多関節に活動性を有する若年性特発性関節炎*・腸管型ベーチェット病・非感染性の中間部,後部又は汎ぶどう膜炎、中等症又は重症の活動期にあるクローン病の寛解導入及び維持療法(既存治療で効果不十分な場合に限る)、中等症又は重症の潰瘍性大腸炎の治療(既存治療で効果不十分な場合に限る)」に係る効能・効果の承認を取得しています。

一般名: アダリムマブ<遺伝子組換え>
販売名: ヒト型抗ヒト TNFα モノクローナル抗体製剤「ヒュミラ皮下注 20mg シリンジ 0.2mL、同 40mg シリンジ 0.4mL、同 80mg シリンジ 0.8mL、同 40mg ペン 0.4mL、同 80mg ペン 0.8mL」

アッヴィについて

アッヴィは、グローバルな研究開発型のバイオ医薬品企業です。世界で最も複雑かつ深刻な疾患に対する、革新的な先進治療薬の開発を行っています。その専門知識、献身的な社員、イノベーション実現に向けた独自の手法を駆使して、免疫疾患、がん、ウイルスおよび神経疾患の 4 つの主要領域における治療に貢献することをミッションに掲げています。世界 75 カ国以上の国において、アッヴィの社員は世界中の人々の健康上の課題に対するソリューションを生み出していくため、日々仕事に取り組んでいます。アッヴィの詳細については、www.abbvie.com をご覧ください。Twitter アカウント@abbvie、Facebook、LinkedIn や Instagram でも情報を公開しています。

日本においては、1,200 人を超える社員が、医療用医薬品の開発、輸入、製造販売に従事しています。自己免疫疾患、新生児、肝疾患、神経疾患、がんの各領域を中心に、患者さんの人生を豊かにしたいと願い、日々の業務に取り組んでいます。詳しくは、www.abbvie.co.jp をご覧ください。

エーザイについて

エーザイ株式会社は、本社を日本に置く研究開発型グローバル製薬企業です。患者様とそのご家族の喜怒哀楽を第一義に考え、そのベネフィット向上に貢献する「ヒューマン・ヘルスケア(hhc)」を企業理念としています。グローバルな研究開発・生産・販売拠点ネットワークを持ち、戦略的重要領域と位置づける「神経領域」「がん」を中心とするアンメット・メディカル・ニーズの高い疾患領域において、世界で約 1 万人の社員が革新的な新薬の創出と提供に取り組んでいます。また、当社は開発途上国・新興国における医薬品アクセスの改善に向け主要なステークホルダーズとの連携を通じ積極的な活動を展開しています。エーザイ株式会社の詳細情報は、www.eisai.co.jp をご覧ください。



Copyright 2020 JCN Newswire. All rights reserved. www.jcnnewswire.com Via JCN Newswire https://ift.tt/2pbRN02

5/28/20

トヨタ自動車、組織改正および幹部職の担当変更・人事異動を発表

Toyota City, Japan, May 29, 2020 - (JCN Newswire) - トヨタ自動車(株)は、6月1日付で下記のとおり、組織改正および幹部職の担当変更、人事異動を行います。

本リリースの詳細は下記URLをご参照ください。
https://global.toyota/jp/newsroom/corporate/32665639.html

概要:トヨタ自動車株式会社

詳細は http://toyota.jp/ をご覧ください。



Copyright 2020 JCN Newswire. All rights reserved. www.jcnnewswire.com Via JCN Newswire https://ift.tt/2pbRN02

Honda、「INSIGHT」をマイナーモデルチェンジし発売

TOKYO, May 29, 2020 - (JCN Newswire) - Hondaは、ハイブリッド車「INSIGHT(インサイト)」をマイナーモデルチェンジし、本日発売いたします。

「シンプルで時代に流されない、本質的な魅力を備えたクルマ」を目指し開発した3代目インサイトは、2018年12月の発売以来、シンプルかつ魅力的なロー&ワイドなデザインや、1.5L e:HEV(イーエイチイーブイ)※がもたらす力強い走りといったクルマの本質を捉えた魅力に加え、ハイブリッド車であることを感じさせない居住空間、また容量519Lのトランクルームといった使い勝手においても、お客さまよりご好評をいただいております。

今回のマイナーモデルチェンジでは、これまでのデザインや走り、使い勝手の良さはそのままに、上質感を一層高めた新グレードの追加や専用装備の設定など、時代に流されないこだわりを持ったお客さまがライフスタイルに合わせてお選びいただけるよう、ラインアップの幅を広げました。

本リリースの詳細は下記をご参照ください。
https://www.honda.co.jp/news/2020/4200529-insight.html

概要:本田技研工業株式会社

詳細は www.honda.co.jp をご覧ください。



Copyright 2020 JCN Newswire. All rights reserved. www.jcnnewswire.com Via JCN Newswire https://ift.tt/2pbRN02

デンソー、役員・執行職の担当変更および人事異動を発表

Aichi, Japan, May 29, 2020 - (JCN Newswire) - 株式会社デンソー(本社:愛知県刈谷市、社長:有馬 浩二)は、当社を取り巻く事業環境の変化に対応すべく、6月1日付でCxO制度に新たな4つのポジションを設置し、変革を推進していきます。 また、以下のとおり、役員・執行職の担当変更および人事異動を実施します。

1. 6月1日付 CxO制度における新ポジションの導入

ポジション/担当役員
CHRO (Chief Human Resources Officer)/副社長 山中 康司
CCRO (Chief Corporate Revolution Officer)/経営役員 篠原 幸弘
CMO (Chief Monozukuri Officer)/経営役員 山崎 康彦
CSwO (Chief Software Officer)/執行職 林 新之助
以上、4つのポジションを加え、当社のCxO制度は11ポジションとなります。
※CxO制度導入については2019年12月25日に発表した「組織変更および人事異動について」をご参照ください。

本リリースの詳細は下記をご参照ください。
https://www.denso.com/jp/ja/news/news-releases/2020/20200529-01/

概要:株式会社デンソー

詳細は https://www.denso.com/jp/ja/ をご覧ください。



Copyright 2020 JCN Newswire. All rights reserved. www.jcnnewswire.com Via JCN Newswire https://ift.tt/2pbRN02

エーザイ、「レンビマ(R)」と「キイトルーダ(R)」の併用療法による切除不能肝細胞がんおよび進行性腎細胞がんに対する臨床試験の解析結果を米国臨床腫瘍学会年次総会において発表

TOKYO, May 29, 2020 - (JCN Newswire) - エーザイ株式会社(本社:東京都、代表執行役 CEO:内藤晴夫、以下 エーザイ)と Merck & Co., Inc., Kenilworth, N.J., U.S.A.(北米以外では MSD)は、このたび、エーザイ創製の経口マルチキナーゼ阻害剤「レンビマ(R)」(一般名:レンバチニブメシル酸塩)と Merck & Co., Inc., Kenilworth, N.J., U.S.A.の抗 PD1 抗体「キイトルーダ(R)」(一般名:ペムブロリズマブ)との併用療法による、全身投与歴のない切除不能肝細胞がん(116/KEYNOTE-524 試験)、および免疫チェックポイント阻害剤治療後に増悪した転移性淡明細胞型腎細胞がん(111/KEYNOTE-146 試験)を対象とした二つの臨床試験解析結果を5月29~31日に開催される「米国臨床腫瘍学会年次総会」(ASCO20 Virtual Scientific Program)において発表することをお知らせいたします。

Merck & Co, Inc., Kenilworth, N.J., U.S.A. Research Laboratories、Oncology Clinical Research の Vice President である Jonathan Cheng 博士は、「これらの試験における「キイトルーダ」と「レンビマ」併用療法の奏効率の高さは、肝細胞がんおよび腎細胞がんにおける本併用療法のポテンシャルの高さを裏付けるものです。本併用療法は Merck のがん臨床研究戦略における重要な柱の一つであり、幅広いがん腫およびそのステージによらず当該臨床試験を進めていきます」と述べています。

エーザイ株式会社の執行役 オンコロジービジネスグループ チーフメディスンクリエーションオフィサー兼チーフディスカバリーオフィサーである大和隆志博士は、「「レンビマ」と「キイトルーダ」の併用療法では、複数の進行がんにおいて一貫したヒューマンエビデンスが獲得、蓄積されており、本併用療法による患者様貢献拡大への我々の熱意と信念がますます強固なものになっています。本併用療法の臨床試験を拡大・継続し、治療が難しいとされたがん患者様に、最先端のサイエンスに基づく有効な治療法を提供し続けていきます」と述べています。

1.切除不能肝細胞がん患者様を対象とした一次療法としてのレンバチニブとペムブロリズマブの併用療法の臨床第Ⅰb 相試験結果(116/KEYNOTE-524 試験、ClinicalTrials.gov: NCT03006926)抄録番号:4519(バーチャルポスターディスカッション)

本試験は、切除不能な肝細胞がん患者様に対する非盲検、単群の臨床第Ⅰb 相試験です。今回の発表では、全身投与治療歴のない 100 人の患者様の最終解析結果が報告されます。「レンビマ」は体重によって 12 mg(60 ㎏以上)または 8 mg(60 ㎏未満)を 1 日 1 回経口投与し、「キイトルーダ」は 3 週ごと200 mg を静脈内投与しました。主要評価項目として、独立画像判定(Independent Imaging Review: IIR)に基づく腫瘍径の変化を効果判定に用いた従来の評価基準(RECIST1.1)、ならびに腫瘍壊死領域を効果判定に加えた評価基準(mRECIST)を用い、奏効率 (Objective Response Rate: ORR)と奏効期間(Duration Of Response: DOR)を評価しました。また、副次評価項目は無増悪生存期間(Progression Free Survival:PFS)、無増悪期間(Time To Progression: TTP)、全生存期間(Overall Survival: OS)でした。データカットオフ時点(2019 年 10 月 31 日)でのフォローアップ期間(中央値)は 10.6 カ月(95%信頼区間 CI: 9.2-11.5)でした。その時点で 37 人の患者様は投与を継続しており(両薬剤継続 34 人、レンビマのみ継続 3 人)、投与継続期間(中央値)は 7.9 カ月(範囲: 0.2 カ月~31.1 カ月)でした。

主要評価項目の最終解析の結果、RECIST1.1 に基づく独立画像判定では、ORR は 36%(95% CI:26.6-46.2)であり、そのうち完全奏効が 1%、部分奏効が 35%でした。また、DOR(中央値)は 12.6 カ月(95% CI: 6.9 カ月-NE(推定不能))でした。mRECIST に基づく独立画像判定では、ORR は 46%(95%CI: 36.0-56.3)であり、そのうち完全奏効が 11%、部分奏効が 35%でした。また、DOR(中央値)は 8.6 カ月(95% CI: 6.9 カ月-NE)でした。

治療関連の有害事象(Treatment-Related Adverse Events: TRAEs)により 6%の患者様で「レンビマ」と「キイトルーダ」の投与を中止しました。同様に 14%の患者様で「レンビマ」の投与を、10%の患者様で「キイトルーダ」の投与を中止しました。グレード 3 以上の有害事象は 67%(グレード 3: 63%、グレード 4:1%, グレード 5: 3%)の患者様で認められました。グレード 4 の有害事象(1 例)は白血球および好中球の減少でした。治療との関連が否定できない死亡が 3 例認められ、内訳は急性呼吸不全/急性呼吸窮迫症候群1例、腸管穿孔1例、肝機能異常1例でした。本併用療法の主な有害事象(20%以上)は、高血圧(36%)、下痢(35%)、疲労(30%)、食欲減退(28%)、甲状腺機能低下症(25%)、手掌足底発赤知覚不全症候群(23%)、体重減少(22%)、発声障害(21%)、アスパラギン酸アミノトランスフェラーゼの増加(20%)、蛋白尿(20%)でした。

2. PD-1/PD-L1 免疫チェックポイント阻害剤治療後に増悪した転移性淡明細胞型腎細胞がん患者様を対象としたレンバチニブとペムブロリズマブ併用療法の臨床第II相試験 (111/KEYNOTE-146 試験, ClinicalTrials.gov: NCT02501096)抄録番号:5008 (バーチャル口頭発表)

111/KEYNOTE-146 試験は、特定の固形がんの患者様を対象とした「レンビマ」と「キイトルーダ」併用療法の安全性と有効性を評価する、非盲検、単群、バスケット型の臨床第Ⅰb/II相試験です。今回の発表では、本試験の臨床第II相試験パートにおける腎細胞がんコホートの最終解析結果であり、PD1/PD-L1 免疫チェックポイント阻害剤治療後に RECIST1.1 によって病勢進行と判定された後、少なくとも4 週間以上経過した転移性淡明細胞型腎細胞がん(mccRCC)の患者様 104 人を対象としています。許容できない有害事象または病勢進行が認められるまで「レンビマ」は 1 日 1 回 20 mg を経口投与し、「キイトルーダ」は 3 週ごと 200 mg を静脈内投与しました。主要評価項目は、腫瘍免疫療法の効果判定基準である immune-related RECIST (irRECIST)による 24 週時点の ORR(ORRweek24)としました。主な副次評価項目は、最大 35 サイクル(約 2 年間)の治療を通じた ORR、PFS、OS と、安全性および忍容性としました。

irRECIST を用いた治験医師による判定では、データカットオフ時点(2020 年 4 月 9 日)でのORRweek24 は 51%(95% CI: 41-61)でした。また、本試験を通じた ORR は 55% (95% CI: 45-65)であり、部分奏効(PR)が 55%、病勢安定(SD)が 36%、病勢進行(PD)が 5%、評価不能が 5%でした。また、DOR(中央値)は 12 カ月(95% CI: 9-18)であり、PFS(中央値)は 11.7 カ月(95% CI: 9.4-17.7)、12 カ月時点で死亡または病勢が進行していない患者様の割合(12-month PFS rate)は 45%(95% CI: 32-57)でした。OS の中央値には到達せず(95% CI: 16.7-NR(not reached))、12 カ月時点で生存している患者様の割合(12-month OS rate)は 77%(95% CI: 67-85)でした。

治験医師による RECIST1.1 を用いた判定では、ORR は 52%(95% CI: 42-62)であり、PR が 52%、SDが 38%、PD が 6%、評価不能が 5%でした。DOR(中央値)は 12 カ月(95% CI: 9-18)、PFS(中央値)は11.3 カ月(95% CI: 7.6-17.7)、12-month PFS rate は 44% (95% CI: 31-55)でした。

治療関連の有害事象により 15%の患者様で「レンビマ」と「キイトルーダ」の投与を中止しました。同様に 12%の患者様で「レンビマ」の投与を、12%の患者様で「キイトルーダ」の投与を中止しました(そのうち2%が蛋白尿)。治療関連の有害事象により 48%の患者様で減薬を必要としました。グレード 4 の有害事象が 4 例認められ、それぞれ、リパーゼの上昇1例、憩室炎 1 例、大腸穿孔1例、心筋梗塞 1 例でした。また、治療との関連が否定できない死亡が 2 例認められ、それぞれ上部消化管出血 1 例、突然死 1 例でした。高頻度に観察された有害事象(20%以上)は、疲労(53%)、下痢(46%)、タンパク尿(39%)、発声困難(35%)、高血圧(34%)、吐き気(32%)、口内炎(32%)、関節痛(29%)、食欲減退(28%)、手掌足底発赤知覚不全症候群(25%)、甲状腺機能低下症(23%)、頭痛(22%)でした。

本リリースの詳細は下記をご参照ください。
https://www.eisai.co.jp/news/2020/news202023.html

概要:エーザイ株式会社

詳細は www.eisai.co.jp をご覧ください。



Copyright 2020 JCN Newswire. All rights reserved. www.jcnnewswire.com Via JCN Newswire https://ift.tt/2pbRN02

Paice, Abell, and Daimler Agree to License Patented Technology

BALTIMORE, MD / ACCESSWIRE, May 29, 2020 - (JCN Newswire) - Paice and Daimler have reached an agreement to license patented hybrid technology.

Paice was an early leader in electrified vehicles. The company was awarded its first hybrid vehicle patent in 1994, long before most automakers began seriously focusing on ways to improve fuel efficiency and reduce emissions. Paice's technology proved valuable and helped accelerate the growth of the hybrid vehicle industry. An independent analysis concluded that Paice owns the most dominant hybrid vehicle patents in the world.

"We've reached several licensing agreements in the past two years without the need for litigation. These agreements make a lasting impact in our community by supporting the good works of the Abell Foundation," said Paice Executive Chairman Frances Keenan.

During the company's early years, Severinsky worked closely with two experienced automotive veterans: Bob Templin, a Paice board member who had served as chief engineer of Cadillac and technical director of GM's Research Laboratory; and Ted Louckes, a 40-year veteran of General Motors who served as Paice's Chief Operating Officer and was instrumental in developing Paice's hybrid technology alongside Dr. Severinsky.

About Paice (www.paicehybrid.com)

Dr. Alex Severinsky, a Russian immigrant, founded Paice in 1992 with the support of the University of Maryland. The company has been awarded 30 U.S. and foreign patents. It has licensing agreements with many of the world's leading automakers.

About the Abell Foundation (www.abell.org)

The Abell Foundation, a Baltimore-based charitable organization dedicated to fighting urban poverty and promoting social objectives by investing in progressive local start-ups, is a co-owner of the Paice patents. Since 1999, Abell has helped support Paice's efforts to develop and promote its hybrid technology.

For More Information
Joyce Fitzpatrick | joyce@fitzpatrickcomm.com | (919) 247-4400

SOURCE: Paice



Copyright 2020 JCN Newswire. All rights reserved. www.jcnnewswire.com Via JCN Newswire https://ift.tt/2pbRN02

Paice, Abell, and Daimler Agree to License Patented Technology

BALTIMORE, MD / ACCESSWIRE, May 29, 2020 - (ACN Newswire) - Paice and Daimler have reached an agreement to license patented hybrid technology.






Paice was an early leader in electrified vehicles. The company was awarded its first hybrid vehicle patent in 1994, long before most automakers began seriously focusing on ways to improve fuel efficiency and reduce emissions. Paice's technology proved valuable and helped accelerate the growth of the hybrid vehicle industry. An independent analysis concluded that Paice owns the most dominant hybrid vehicle patents in the world.

"We've reached several licensing agreements in the past two years without the need for litigation. These agreements make a lasting impact in our community by supporting the good works of the Abell Foundation," said Paice Executive Chairman Frances Keenan.

During the company's early years, Severinsky worked closely with two experienced automotive veterans: Bob Templin, a Paice board member who had served as chief engineer of Cadillac and technical director of GM's Research Laboratory; and Ted Louckes, a 40-year veteran of General Motors who served as Paice's Chief Operating Officer and was instrumental in developing Paice's hybrid technology alongside Dr. Severinsky.

About Paice (www.paicehybrid.com)

Dr. Alex Severinsky, a Russian immigrant, founded Paice in 1992 with the support of the University of Maryland. The company has been awarded 30 U.S. and foreign patents. It has licensing agreements with many of the world's leading automakers.

About the Abell Foundation (www.abell.org)

The Abell Foundation, a Baltimore-based charitable organization dedicated to fighting urban poverty and promoting social objectives by investing in progressive local start-ups, is a co-owner of the Paice patents. Since 1999, Abell has helped support Paice's efforts to develop and promote its hybrid technology.

For More Information
Joyce Fitzpatrick | joyce@fitzpatrickcomm.com | (919) 247-4400

SOURCE: Paice

Copyright 2020 ACN Newswire. All rights reserved. www.acnnewswire.com

source http://www.acnnewswire.com/press-release/english/59284/

Sino Biopharmaceutical Announces 2020 First Quarterly Results

HONG KONG, May 28, 2020 - (ACN Newswire) - Sino Biopharmaceutical Limited ("Sino Biopharmaceutical" or the "Company", together with its subsidiaries, the "Group") (HKEX:1177), a leading, innovative research and development ("R&D") driven pharmaceutical conglomerate in the PRC, has announced its unaudited first quarterly results for the three months ended 31 March 2020 ("the review period").

Results Highlights
- At the beginning of the COVID-19 pandemic, owing to its strong sense of social responsibility and in line with its mission, the Group took the initiative to donate RMB10 million to the Chinese Academy of Medical Sciences on 26 January to support research on COVID-19. At the same time, the Group has promptly set up an anti-pandemic supplies procurement team to purchase supplies, such as face masks, protective gloves, protective clothing, negative pressure isolation ambulances and diagnosis and treatment related products, from different countries for donating to anti-pandemic frontline medical workers. Up to the end of the period, Sino Biopharm and its subsidiaries donated cash and supplies on 18 different occasions with a total value of nearly RMB22 million to anti-pandemic efforts.

- "The Establishment and Application of Key Technology Systems on Emulsification in New Pharmaceutical Preparation," a research project reported by Beijing Tide, in cooperation with Peking University, has been honoured with "The 2019 National Science and Technology Progress Award - Second Prize". The Group is one of the few pharmaceutical enterprises to be feted in this way. The accolade is prestigious national recognition of Beijing Tide's research and development platform of emulsification for high-end preparations.

- Construction of "The Purun Bio-Medical's R&D and Production Project" of Jiangsu Purun Bio-Medical Co., Ltd., a wholly-owned subsidiary of NJCTT located at Nanjing Jiangbei New Materials High-Tech Park, has officially commenced after the groundbreaking ceremony. Occupying an area of about 300 mu, NJCTT's product R&D and production capabilities would be substantially strengthened after the project is completed.

- The Group has obtained approval from the United States Food and Drug Administration ("FDA") for its application filed for "Fulvestrant Injection". This is another advance for the Group to sell its products in the international markets after Tenofovir Disoproxil Fumarate tablets obtained marketing authorization in the European Union.

- During the pandemic, the intravenous therapy of Magnesium Isoglycyrrhizinate injection (brand name: Tianqingganmei) was included as a supportive treatment for patients with mild and common symptoms (without severe underlying illnesses) in the "Treatment Practices for the Mild and Common Cases of Novel Coronavirus Pneumonia (Second Edition)" jointly published by the offices of the National Health Commission and National Administration of Traditional Chinese Medicine.

- Five products including "Budesonide Suspension for Inhalation" (brand name: Tianqingsuchang), "Sitagliptin Phosphate Tablet" and "Dabigatran Etexilate Capsules" (two specifications) obtained approval for drug registration. Three of these products are the first generic drug of their kind in China and have potential to become blockbuster products.

Results
For the three months ended 31 March 2020, the Group recorded revenue of approximately RMB6.22 billion, representing an increase of approximately 0.2% over the same period last year. During the period, profit attributable to the owners of the parent was approximately RMB862 million, approximately 0.6% higher than that of the same period last year. Earnings per share were approximately RMB6.85 cents, 0.7% higher than that of the same period last year. The Group has maintained a strong financial position with cash and bank balances reaching approximately RMB16.12 billion at the period end (as at 31 December 2019: approximately RMB11.91 billion).

The Board of Directors declared a quarterly dividend of HK2 cents per share (2019 first quarter: HK2 cents).

Business Highlights
During the period under review, most outpatient and inpatient visits at hospitals dropped dramatically due to the pandemic. On-site academic activities and face-to-face exchanges with professional doctors were also adversely affected. The Group quickly reacted and fully utilized third-party online academic exchange platforms to maintain communication with general medical practitioners and patients, thereby strengthening its support to online academic activities. Particularly in the areas of respiratory, infection and oncology that have been less affected by the pandemic, intensive online academic exchanges and promotion activities have been launched. The Group has also supported volunteer medical consultations taking place through online hospital networks. The chronic disease management platform of the Group for respiratory, oncology, analgesic, and kidney illnesses that has been actively operating was also used to enhance the service and professional assistance provided to doctors and patients.

For the production, in response to the government's strategies, the Group has resumed its production and operations at the early stage with strict precautions for isolation and social distancing, with the first priority to ensure the supply of much-needed anti-infection and respiratory drugs for the therapy of those patients infected with COVID-19, as well as the oncology drugs with pressing demand. The respiratory medicine Tianqingsule (Tiotropium Bromide powder for inhalation); anti-infectious medicines Tianjie (Tigecycline for Injection), Fengruineng (Moxifloxacin Hydrochloride and Sodium Chloride Injection), Tianli (Linezolid and Glucose Injections), and Tianming (Caspofungin Acetate for Injection); analgesics Flurbiprofen cataplasm and Parecoxib Sodium for Injection; and orthopedic medicine Gaisanchun (Calcitriol) capsules also recorded strong growth.

The sales from oncology drugs recorded the highest growth among all. In addition to the rapid growth of Anlotinib Hydrochloride capsules, sales of two products: Qingkeshu (Abiraterone Acetate Tablets), and Jizhi (Gefitinib Tablets) rapidly expanded after they secured the bid for the extended centralized drug procurements by the government. Other oncology products Yinishu (Dasatinib) tablets, Qianping (Bortezomib for Injection) and Shoufu (Capecitabine) tablets also recorded strong growth, which further enlarged the sales contribution of the oncology drug lines to the Group.

The newly launched products also significantly boosted the sales growth. In addition to Qingkeshu, and Jizhi mentioned above, products that have been approved for launch also recorded satisfactory results, including cardiovascular medicine Anbeining (Apixaban Tablets), contrast agent Qingliming (Iodixanol Injection), the first generic oncology drug Leweixin (Bendamustine Hydrochloride for Injection), Weishou (Azacitidine for Injection, the first generic drug) and the first generic anti-rheumatic drug Taiyan (Tofacitinib Citrate Tablets).

For R&D, several strategic products with strong potential have secured production approvals during the period, and 4 of them have been designated as meeting the Consistency Evaluation requirements at the same time.

During the review period, the sales performance of the Group's major medicine types are outlined below:

Hepatitis medicines
- The sales of hepatitis medicines amounted to approximately RMB1,329.61 million, representing approximately 21.4% of the Group's revenue.

Oncology medicines
- The sales of oncology medicines amounted to approximately RMB1,984.40 million, representing approximately 31.9% of the Group's revenue.

Orthopedic medicines
- The sales of orthopedic medicines amounted to approximately RMB467.75 million, representing approximately 7.5% of the Group's revenue.

Anti-infectious medicines
- The sales of anti-infectious medicines amounted to approximately RMB416.01 million, representing approximately 6.7% of the Group's revenue.

Respiratory system medicines
- The sales of respiratory medicines amounted to approximately RMB334.41 million, representing approximately 5.4% of the Group's revenue.

Others
- Sales of other medicines amounted to approximately RMB1,689.69 million, representing approximately 27.1% of the Group's revenue.

R&D
The Group has continued to focus its R&D efforts on new hepatitis, oncology and respiratory system and cardio-cerebral medicines. During the first quarter, the Group was granted 14 clinical trial approvals, 6 production approvals, and 6 approvals for Consistency Evaluation, and made 9 clinical trial applications, 3 applications for Consistency Evaluation and 2 production applications. Cumulatively, a total of 437 pharmaceutical products had obtained clinical trial approval, or were under clinical trial or applying for production approval. Out of these, 30 were for hepatitis medicines, 189 for oncology medicines, 24 for respiratory system medicines, 24 for endocrine, 40 for cardio-cerebral medicines and 130 for other medicines.

Over the years, the Group has been placing high importance on R&D and innovation, as well as through collaboration and imitation, to raise both R&D standards and efficiency. Regarding R&D as the lifeblood of the Group's development, the Group continues to devote into more resources. For the three months ended 31 March 2020, the total R&D expenditure of approximately RMB994 million, which accounted for approximately 16.0% of the Group's revenue, was charged to the statement of profit or loss and capitalized in the statement of financial position respectively.

The Group also emphasizes on the protection of intellectual property rights. It encourages its enterprises to apply for patent applications as a means to enhance the Group's core competitiveness. During the first quarter, the Group has received 25 authorized patent notices (21 invention patents, 2 utility model patents and 2 apparel design patents) and filed 123 new patent applications (120 invention patents and 3 apparel design patents). Cumulatively, the Group has obtained 787 invention patent approvals, 25 utility model patents and 92 apparel design patents.

Prospects
The COVID-19 pandemic remains serious in regions outside China, which will continue to affect the economy. Through implementing effective prevention and control measures, the pandemic in China has essentially come under control and enterprises around the country have gradually resumed work and operation. The decline in economic indicators has also narrowed. Hence, China is expected to be among the first countries to leave the worst impact of the pandemic behind and return to normal production, everyday life and routine medical procedures. Pent-up demand for medical diagnosis and treatment limited by isolation during the pandemic period will gradually be unleashed, which might lead to the rapid growth for the pharmaceutical industry in the immediate future.

The nationwide implementation and extension of the centralized drug procurement programme in "4+7" cities has substantially squeezed the profit of selected drugs as well as many competitive generic drugs. The COVID-19 pandemic has weighed further on the operations of small- and medium-pharmaceutical companies with limited R&D capabilities and only a few new products. Some of them are even encountering difficulties in maintaining the viability of their business. As a result, the consolidation and elimination of the weaker players in the market will accelerate and developing and launching innovative and popular products have become the primary capabilities required by pharmaceutical enterprises if they wish to win amidst the fiercer market competition.

The Group's strong investment in R&D over the years has borne fruit, as evidenced by the maturing innovative platforms and optimization of creative talent structure for both small molecule and macro-molecule drugs. The continuous huge investment in R&D has also ensured that it can engage in the launch of new products every year, which has become and will continue to be the key growth driver for the Group's results.

Introduction of Newly Approved Products:
Tianqingsuchang (Budesonide Suspension for Inhalation): A glucocorticoid inhalant with strong anti-inflammatory properties used for first-line treatment of asthma. There are approximately 235 million asthma patients globally, and the number in China exceeds 45 million. The efficacy of nebulized inhalation suspension is more trusted by doctors and patients when compared to other dosage forms but needs to be administered under the supervision of medical professionals in hospitals.

Sitagliptin Phosphate Tablet: An effective and highly selective dipeptidyl peptidase-4 (DPP-4) inhibitor used for improving glycemic control in patients with type 2 diabetes mellitus. Clinical trials show its efficacy in lowering blood sugar, and it can be used alone with high safety and fair tolerance, without increasing the risk of hypoglycemia and causing gastrointestinal reactions. More importantly, it offers long-term protection of beta-cells in the pancreas, which can slow the progress of diabetes.

Dabigatran Etexilate Capsules: A new generation non-Vitamin K oral anticoagulant used for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation. It is the first new oral anticoagulant launched since Warfarin in 50 years, and is the first oral anticoagulant approved for long term indications, signifying a milestone in the global anticoagulant drug sector.

About Sino Biopharmaceutical Limited (HKEX:1177)
Sino Biopharmaceutical Limited is a leading, innovative R&D driven pharmaceutical conglomerate in the PRC. Its business encompasses a fully-integrated chain which covers an array of R&D platforms, a line-up of intelligent production and a strong sales system. The Group's products have gained a competitive foothold in various therapeutic categories with promising potentials, comprising a variety of biopharmaceutical and chemical medicines for treating tumors, liver diseases, respiratory system diseases, anti-infectious diseases and orthopedic diseases.

Sino Biopharm is a constituent stock of the following indices: MSCI Global Standard Indices - MSCI China Index, Hang Seng Index, Hang Seng Index - Commerce & Industry, Hang Seng Composite Index, Hang Seng Composite Industry Index - Consumer Goods, Hang Seng Composite LargeCap Index, Hang Seng Composite LargeCap & MidCap Index, Hang Seng China (Hong Kong-listed) 100 Index and Hang Seng Stock Connect Hong Kong Index. Sino Biopharm was ranked as one of "Asia's Fab 50 Companies" by Forbes Asia for three consecutive years in 2016, 2017 and 2018.


Copyright 2020 ACN Newswire. All rights reserved. www.acnnewswire.com

source http://www.acnnewswire.com/press-release/english/59281/